Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal To Fight Zika Virus Boosts NIH, CDC Efforts, But Offers No FDA Review Dollars

This article was originally published in The Gray Sheet

Executive Summary

A $1.1bn agreement between the House and Senate to fund the emergency Zika virus response gives millions of dollars to the Centers for Disease Control and Prevention, NIH, and HHS's biodefense unit, but leaves FDA with no extra funds to support reviews of Zika products. The deal would take dollars from Ebola funding and HHS Affordable Care Act efforts as an offset, and is opposed by the president, who says he will veto it.

Advertisement

Related Content

Quest For Political Capital, Legacy Could Push 'Cures' Over The Finish Line
Medtech In Politics: A Look At Republican And Democratic Party Platforms

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT038358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel